ReviewNano convergence2023
Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy.
Review in Nano convergence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 76 citations in OpenAlex.
- Rewriting the mRNA Delivery Map: Albumin Hitchhiking Lipid Nanoparticles for Safer and Smarter Nanomedicine.ACS materials Au · 2026Review
- Critical Evaluation of Key Methods for RNA Quantification.International journal of molecular sciences · 2026Review
- Antibody reveals conformational latch regulating dimerization in β- and γ-herpesvirus proteases.Nature communications · 2026Article
- Development of a microneedle patch for delivery of mRNA-lipid nanoparticles.Drug delivery and translational research · 2026Article
- In Vivo Tracking Modalities for Oncolytic Reovirus: Principles, Clinical Applications, and Translational Integration.Molecular imaging and biology · 2026Review
- Discovery of Novel Ionizable Lipids for Lipid Nanoparticles: Lipophilicity as a Predictor of Squaramide Head Group Lipid Clearance.Small science · 2026Article
- Gauging lipid vulnerabilities in mRNA-LNPs under various environmental stressors through TIMS-TOF analysis.RSC advances · 2026Article
- Structurally-optimised HPV16 E7/E6 mRNA-LPP mediates dose-sparing efficacy via tumour microenvironment reprogramming.Molecular biomedicine · 2026Article
- Exogenous CD55 Expression on Membrane-Wrapped Nanoparticles Unexpectedly Increases Spleen Tropism and Immune Cell UptakeACS nano medicine · 2026Article
- Examining the effect of lipid nanoparticle elasticity on endocytosis and mRNA delivery to cancer cells.Med-X · 2026Article
- Nanomedicine for Cancer and Autoimmune Immunotherapy.International journal of molecular sciences · 2025Review
- Targeted nanoliposomal nutrient delivery for human health.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Size control of lipid nanoparticles via simulation-based design of a microfluidic chip and its effect on mRNA delivery in vitro and in vivo.Journal of nanobiotechnology · 2025Article
- Antibody Reveals Conformational Latch Controlling Herpesvirus Proteases.bioRxiv : the preprint server for biology · 2025Article
- Pre-clinical evaluation of mRNA-lipid nanoparticles' potency and toxicity: current practices and future directions.In vitro models · 2025Review
- Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine.Cancer medicine · 2025Review
- Nanobody-Decorated Lipid Nanoparticles for Enhanced mRNA Delivery to Tumors In Vivo.Advanced healthcare materials · 2025Article
- Current perspectives and global trends of nanotechnology in advanced breast cancer: a bibliometric and visualized analysis.Discover oncology · 2025Article
- Prospects and Challenges of Lung Cancer Vaccines.Vaccines · 2025Review
- Intratumoral Immunotherapy with Cowpea Mosaic Virus and Interleukin-12 Eliminates Established Treated Tumors and Generates Robust Systemic Immunity to Suppress the Growth of Untreated Metastatic Tumors.Molecular pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Cancer immunotherapy, which harnesses the power of the immune system, has shown immense promise in the fight against malignancies. Messenger RNA (mRNA) stands as a versatile instrument in this context, with its capacity to encode tumor-associated antigens (TAAs), immune cell receptors, cytokines, and antibodies. Nevertheless, the inherent structural instability of mRNA requires the development of effective delivery systems. Lipid nanoparticles (LNPs) have emerged as significant candidates for mRNA delivery in cancer immunotherapy, providing both protection to the mRNA and enhanced intracellular delivery efficiency. In this review, we offer a comprehensive summary of the recent advancements in LNP-based mRNA delivery systems, with a focus on strategies for optimizing the design and delivery of mRNA-encoded therapeutics in cancer treatment. Furthermore, we delve into the challenges encountered in this field and contemplate future perspectives, aiming to improve the safety and efficacy of LNP-based mRNA cancer immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.